Davita clinical research study finds efficacy of common covid-19 vaccines at parity for kidney patients

Denver, feb. 17, 2022 /prnewswire/ -- dialysis patients who received an adenovirus vector-based covid-19 vaccine (johnson & johnson) were found to have similar rates of breakthrough infection, hospitalization and mortality as dialysis patients who received an mrna-based vaccine (pfizer/biontech), according to a davita clinical research (dcr) study published online ahead of print by the journal of the american society of nephrology. "vaccination remains the most effective manner of preventing severe illness due to covid-19 for dialysis patients," said dr. steven brunelli, mcse, vice president for dcr.
DVA Ratings Summary
DVA Quant Ranking